Key result
This editorial reviews paradigm shifts in treating stable ischemic heart disease, highlighting that the optimal threshold of ischemia for revascularization versus medical therapy remains undefined.
Why the study?
Does percutaneous coronary intervention added to optimal medical therapy improve long-term survival in patients with stable ischemic heart disease?
Does percutaneous coronary intervention added to optimal medical therapy improve long-term survival in patients with stable ischemic heart disease?
Answers are grounded in this paper and cite their sources.
This editorial emphasizes that the threshold of ischemia severity at which revascularization provides a survival benefit over medical therapy alone in stable ischemic heart disease remains undefined.
HomeCirculation: Cardiovascular Quality and OutcomesVol. 12, No. 2Paradigm Shifts in the Treatment of Stable Ischemic Heart Disease Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBParadigm Shifts in the Treatment of Stable Ischemic Heart DiseaseWhere Do We Draw the Line? Srinath Adusumalli, MD, MSc and Jay Giri, MD, MPH Srinath AdusumalliSrinath Adusumalli Srinath Adusumalli, MD, MSc, Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 11-139 PCAM S Pavilion, 3400 Civic Center Blvd, Philadelphia, PA 19104. Email E-mail Address: [email protected] Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia. Cardiovascular Outcomes, Quality, and Evaluative Research Center and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia. and Jay GiriJay Giri Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia. Cardiovascular Outcomes, Quality, and Evaluative Research Center and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia. Originally published18 Feb 2019https://doi.org/10.1161/CIRCOUTCOMES.118.005388Circulation: Cardiovascular Quality and Outcomes. 2019;12:e005388This article is a commentary on the followingEffect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart DiseaseSee Article by Weintraub et alThe therapy of stable ischemic heart disease (SIHD) and its cardinal symptom, angina pectoris, has been in evolution almost since it was first described by English physician William Heberden in 1768. The past 3 decades have been a particularly active time during which there have been monumental shifts in paradigms for the treatment of SIHD driven by emerging science. In 1994, Yusuf et al1 showed, via patient-level meta-analysis, that coronary artery bypass grafting surgery conferred 42% and 68% reductions in the risk of 10-year mortality in patients with stable 3-vessel and left main coronary artery disease (CAD), respectively. That publication laid the groundwork for class I American Heart Association/American College of Cardiology guideline recommendations that coronary artery bypass grafting surgery be performed for patients with 3-vessel and left main CAD.2 Patients with this degree of anatomic disease leading to large territory ischemia presumably benefit via reductions in incidence of ischemic cardiomyopathy, ischemia-mediated arrhythmias, and myocardial infarctions. This latter point about myocardial infarction was further illustrated by the recent publication of the FAME-2 trial (Five-Year Outcomes With PCI Guided by Fractional Flow Reserve) which showed that ischemia/fractional flow reserve-guided revascularization significantly reduced the risk of myocardial infarction at 5 years.3 Overall, through this body of work, we have learned that coronary revascularization in patients with large-territory ischemia improves survival and reduces future cardiovascular events.What, then, is the role of percutaneous coronary intervention (PCI) in patients with ischemia? Shaw et al4 examined this question in a prespecified substudy of the original COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).5 In that study, the authors found that adding PCI to optimal medical therapy (OMT) resulted in a statistically significantly larger reduction of inducible ischemia (2.7%) as compared to OMT (0.5%) alone, particularly in those with moderate to severe pretreatment ischemia.4 More recently, Al-Lamee et al6 confirmed these findings in a subanalysis of the ORBITA trial (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) in which investigators demonstrated that PCI reduced inducible ischemia as assessed by stress echocardiography values. Nearly contemporaneously, Cook et al7 demonstrated that PCI is associated with immediate reductions in inducible ischemia as assessed by fractional flow reserve, instantaneous wave-free ratio, and coronary flow reserve. Taken together, it seems that PCI, as compared with OMT, more completely reduces ischemia as measured by a variety of indicators.It is in this context that, in this issue of Circulation: Cardiovascular Quality and Outcomes, Weintraub et al8 report the results of a post hoc analysis of the COURAGE trial extended follow-up data set examining the association between the number of diseased coronary arteries as well as severity of ischemia with long-term survival. The original COURAGE trial, conducted between 1999 and 2004 and published in 2007, randomly assigned 2287 patients with SIHD to an initial management strategy of OMT alone versus OMT+PCI.5 Over a median follow-up period of 4.6 years, there was no significant difference in the rate of survival. Long-term survival results for patients followed up to 15 years were consistent with the original study findings in that there was no difference in survival between the OMT and OMT+PCI study groups.9 Notably, patients with unprotected left main CAD as well as markedly positive stress tests indicating a large degree of ischemia were excluded from the study population. Additionally, a minority of patients (30%) had angiographic 3-vessel or proximal left main CAD. In the current study, Weintraub et al8 found that, during a median follow-up of 7.9 years and maximum follow-up of 15 years, the number of coronary arteries diseased (assessed by quantitative coronary angiography) and the severity of ischemia (assessed by single photon emission computed tomography myocardial perfusion imaging) were not significantly associated with long-term survival after adjustment for baseline patient characteristics. Furthermore, they noted there was no interaction between OMT and OMT+PCI treatment groups and CAD/ischemia severity groups where OMT+PCI conferred a survival advantage. Finally, the authors found that baseline variables such as age, tobacco use, diabetes mellitus, heart failure, blood pressure, and left ventricular ejection fraction were all independent predictors of survival and likely associated with burden and progression of CAD.The authors should be commended for completing a rigorous post hoc analysis of the COURAGE trial data set that meaningfully adds to the SIHD literature, especially in the arena of diagnostic evaluation and treatment of patients with intermediate-risk CAD. It is clear that an initial strategy of OMT in a population of patients who resemble those enrolled in the COURAGE trial does not adversely impact long-term survival. There are, however, several limitations to their analysis, many of which are acknowledged in their article. First, although the original COURAGE trial included 2287 patients, only 1379 (60%) of those patients met the inclusion criteria of having both quantitative coronary angiography and single photon emission computed tomography data for this study. The included group of patients did differ in a statistically significant manner from the original COURAGE study group with regards to several important baseline characteristics (Table 1), raising the question of selection bias in the current study. Additionally, only 767 patients (56%) had extended follow-up data available and this group also differed with regards to baseline characteristics as outlined in Table I in the Data Supplement, also raising concerns of selection bias and study generalizability. The methods with which ischemia (6 segment model single photon emission computed tomography myocardial perfusion imaging interpreted at study sites) and the burden of CAD (number of diseased vessels) were assessed lack precision and may blunt any associations between disease severity and long-term survival that may be present. Additionally, similar to the initial extended follow-up report from COURAGE, information about subsequent revascularization after the original study period is unavailable. The steady crossover of patients initially treated with OMT alone to PCI serves to obscure our ability to detect any effect of PCI if it exists. Thus, it is worth reemphasizing that COURAGE as well as subsequent important trials such as FAME-2 and ORBITA, tested only an initial strategy of OMT alone with patients and physicians commonly opting for PCI in follow-up based on clinical circumstances. We do not have good information on patient outcomes, both clinical and symptom-related, for a population of patients with SIHD that is prohibited from revascularization over intermediate to long-term follow-up. Finally, the COURAGE trial included few patients with severe CAD as well as those with severe left ventricular systolic dysfunction, and the results of the current study should not be taken to apply to patients with those conditions.How do we reconcile the results of this analysis with our knowledge, as previously described, that coronary revascularization historically reduced the risk of mortality in patients with large degrees of anatomic CAD/ischemia and that PCI does reduce ischemic burden? Is there a threshold of ischemia which, when surpassed in an all-comer patient population, confers a mortality benefit when treated with PCI or coronary artery bypass graft? It is interesting that while the debate about PCI for SIHD in general is heated, very few people question the value of revascularization in stable, severe left main CAD. Given this, it seems that current arguments about revascularization are not necessarily debating the principle of relieving ischemia, but rather the threshold at which this may provide meaningful clinical benefit. What is this threshold and, if it exists, where should we draw the line where we deploy initial OMT versus initial revascularization therapies? Although many clinicians intuitively practice with this principle in mind, this question remains unanswered in the medical literature.The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), which closed to recruitment in January 2018, aims to provide insights into this question in a population of patients with imaging evidence of moderate to severe ischemia.10 Even before publication, however, the ISCHEMIA trial has come under criticism for prespecified changes in its primary end point (to include more subjective outcomes such as hospitalization for unstable angina and heart failure which may be victim to the influence of physicians and subjects that are not blinded to treatment assignment) as well as modifying its definition of ischemia.11,12 In reality, ISCHEMIA was always intended to be one more well-done trial, in the context of a wealth of historical information, that incrementally improved our understanding of SIHD. Regardless of the recent uproar over the modifications noted above, this remains the case. It is difficult to accept that we are unlikely to be presented with an algorithmic yes/no answer about revascularization for the individual patient with SIHD by ISCHEMIA or any other single trial. However, as medical/interventional technologies as well our techniques for patient assessment evolve, we may be better off accepting that paradigms around the treatment of SIHD are a complex and moving target, one that is worthy of a continuing process of investigation rather than an elusive search for a magic bullet.DisclosuresDr Giri is on the Board of Directors for the Pulmonary Embolism Response Team Consortium—a 501(c)(3) not-for-profit organization. He is on the Advisory Board for Astra Zeneca. He has received research funds directed to his institution from St. Jude Medical and Recor Medical. The other author reports no conflicts.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Srinath Adusumalli, MD, MSc, Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 11-139 PCAM S Pavilion, 3400 Civic Center Blvd, Philadelphia, PA 19104. Email sri.[email protected]upenn.eduReferences1. Yusuf S, Zucker D, Passamani E, Peduzzi P, Takaro T, Fisher L., Kennedy J, Davis K, Killip T, Norris R, Morris C, Mathur V, Varnauskas E, Chalmers T. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by Coronary Artery Bypass Graft Surgery Trialists Collaboration.Lancet. 1994; 344:563–570.CrossrefMedlineGoogle Scholar2. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams SV; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.J Am Coll Cardiol. 2012; 60:e44–e164. doi: 10.1016/j.jacc.2012.07.013CrossrefMedlineGoogle Scholar3. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, Engstrøm T, Kääb S, Dambrink JH, Rioufol G, Toth GG, Piroth Z, Witt N, Fröbert O, Kala P, Linke A, Jagic N, Mates M, Mavromatis K, Samady H, Irimpen A, Oldroyd K, Campo G, Rothenbühler M, Jüni P, De Bruyne B; FAME 2 Investigators. Five-year outcomes with PCI guided by fractional flow reserve.N Engl J Med. 2018; 379:250–259. doi: 10.1056/NEJMoa1803538CrossrefMedlineGoogle Scholar4. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.Circulation. 2008; 117:1283–1291. doi: 10.1161/CIRCULATIONAHA.107.743963LinkGoogle Scholar5. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med. 2007; 356:1503–1516. doi: 10.1056/NEJMoa070829CrossrefMedlineGoogle Scholar6. Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, Nijjer S, Petraco R, Davies J, Keeble T, Tang K, Malik IS, Cook C, Ahmad Y, Sharp ASP, Gerber R, Baker C, Kaprielian R, Talwar S, Assomull R, Cole G, Keenan NG, Kanaganayagam G, Sehmi J, Wensel R, Harrell FE, Mayet J, Thom SA, Davies JE, Francis DP. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease.Circulation. 2018; 138:1780–1792. doi: 10.1161/CIRCULATIONAHA.118.033801LinkGoogle Scholar7. Cook CM, Ahmad Y, Howard JP, Shun-Shin MJ, Sethi A, Clesham GJ, Tang KH, Nijjer SS, Kelly PA, Davies JR, Malik IS, Kaprielian R, Mikhail G, Petraco R, Al-Janabi F, Karamasis GV, Mohdnazri S, Gamma R, Al-Lamee R, Keeble TR, Mayet J, Sen S, Francis DP, Davies JE. Impact of percutaneous revascularization on exercise hemodynamics in patients with stable coronary disease.J Am Coll Cardiol. 2018; 72:970–983. doi: 10.1016/j.jacc.2018.06.033CrossrefMedlineGoogle Scholar8. Weintraub WS, Hartigan PM, Mancini GBJ, Teo KK, Maron DJ, Spertus JA, Chaitman BR, Shaw LJ, Berman DS, Boden WE; on behalf of the COURAGE Trial Investigators. Effect of coronary anatomy and myocardial ischemia on long-term survival in patients with stable ischemic heart disease.Circ Cardiovasc Qual Outcomes. 2019; 12:e005079. doi: 10.1161/CIRCOUTCOMES.118.005079LinkGoogle Scholar9. Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE; COURAGE Trial Investigators. Effect of PCI on long-term survival in patients with stable ischemic heart disease.N Engl J Med. 2015; 373:1937–1946. doi: 10.1056/NEJMoa1505532CrossrefMedlineGoogle Scholar10. Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB, Williams DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design.Am Heart J. 2018; 201:124–135. doi: 10.1016/j.ahj.2018.04.011CrossrefMedlineGoogle Scholar11. Rajkumar CA, Nijjer SS, Cole GD, Al-Lamee R, Francis DP. 'Faith healing' and 'subtraction anxiety' in unblinded trials of procedures.Circ Cardiovasc Qual Outcomes. 2018; 11:e004665. doi: 10.1161/CIRCOUTCOMES.118.004665LinkGoogle Scholar12. Murthy VL, Eagle KA. ISCHEMIA: a search for clarity and why we may not find it.Am Heart J. 2018; 203:82–84. doi: 10.1016/j.ahj.2018.03.031CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesEffect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart DiseaseWilliam S. Weintraub, et al. Circulation: Cardiovascular Quality and Outcomes. 2019;12 February 2019Vol 12, Issue 2 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/CIRCOUTCOMES.118.005388PMID: 30773026 Originally publishedFebruary 18, 2019 Keywordsmyocardial infarctionheart failureblood pressureincidencecoronary artery diseaseEditorialsPDF download Advertisement SubjectsCoronary Artery Disease
No takes yet. Share an insight, caveat, or question.
Adusumalli et al. (2019) conducted an editorial in Stable Ischemic Heart Disease. This editorial reviews paradigm shifts in treating stable ischemic heart disease, highlighting that the optimal threshold of ischemia for revascularization versus medical therapy remains undefined.
Synapse has enriched 10 related papers. Consider them for comparative context: